Literature DB >> 34256860

Prevalence of an angiotensin-converting enzyme gene variant in dogs.

D B Adin1, C E Atkins2, S G Friedenberg3, J A Stern4, K M Meurs2.   

Abstract

BACKGROUND: Genetic heterogeneity of the canine angiotensin converting enzyme (ACE) gene is functionally important because the degree of aldosterone breakthrough with ACE-inhibitor therapy is greater in variant positive dogs compared to variant negative dogs, but the prevalence of the variant is not known. The purpose of this study was to determine ACE gene variant-positive prevalence in a population of 497 dogs of different breeds.
RESULTS: Overall variant-positive prevalence was 31%, with 20% of dogs heterozygous and 11% of dogs homozygous. The variant was overrepresented in Irish Wolfhounds (prevalence 95%; P < .001), Dachshunds (prevalence 90%; P < .001), Cavalier King Charles Spaniels (prevalence 85%; P < .001), Great Danes (prevalence 84%; P < .001), and Bull Mastiffs (prevalence 58%; P = .02). Irish Wolfhounds were more likely to be homozygous than heterozygous (P < .001).
CONCLUSIONS: Nearly one-third of dogs in this study were positive for a functionally important ACE gene variant, with wide prevalence variability between breeds. The clinical importance of high ACE gene variant-positive prevalence in some breeds requires further study because the highest prevalences were found in breeds that are predisposed to heart disease and therefore may be treated with ACE-inhibitors.
© 2021. The Author(s).

Entities:  

Keywords:  Aldosterone breakthrough; Genotype; Heart; Renin-angiotensin aldosterone system

Year:  2021        PMID: 34256860     DOI: 10.1186/s40575-021-00105-2

Source DB:  PubMed          Journal:  Canine Med Genet        ISSN: 2662-9380


  1 in total

1.  Dilated cardiomyopathy in 151 Irish Wolfhounds: Characteristic clinical findings, life expectancy and causes of death.

Authors:  C Vollmar; A Vollmar; B W Keene; P R Fox; S Reese; B Kohn
Journal:  Vet J       Date:  2018-12-18       Impact factor: 2.688

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.